SWOG clinical trial number
SWOG-9230

Evaluation of Interleukin-4 (IL-4) in Disseminated Renal Cell Adenocarcinoma, Phase II

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Renal
Activated
06/01/1993
Closed
05/01/1995

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

2002

Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study

RP Whitehead;D Lew;RC Flanigan;GR Weiss;V Roy;LM Glode;SR Dakhil;ED Crawford Journal of Immunotherapy 25(4):352-358

1996

Phase II trial of recombinant human interleukin-4 (rhuIL-4) in patients with disseminated renal cell adenocarcinoma: A Southwest Oncology Group (SWOG) study.

RP Whitehead;B Blumenstein;RC Flanigan;GR Weiss;DJ Culkin;SI Bearman;S Dakhil;ED Crawford American Society of Clinical Oncology 15:259(#672)

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA8185

Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase